AgomAb raises €62M in Series B round to advance regenerative medicine
Labiotech - 16-Mar-2021Funds to bring the experimental drug to trials; symbolizes booming regenerative niche
The Live Forever Club is evolving. Subscribe to the newsletter to be the first to hear about this important change.
Journalist interested in international politics, business, technology, and innovation
Victor is a journalist based from Istanbul writing about international politics, business, technology, and innovation. He has written for Fast Company, USA Today, Globe and Mail, The Atlantic, Washington Times, the Balkan Investigative Reporting Network, International Business Times and others.
He completed M.A. in Journalism at New York University, International Peace studies at University of Notre Dame.
Visit website: https://www.labiotech.eu/author/victor-kotsev/
See alsoDetails last updated 06-Jul-2021
Funds to bring the experimental drug to trials; symbolizes booming regenerative niche